Institute of Endemic Diseases, University of Khartoum, Sudan.
Am J Trop Med Hyg. 2011 Oct;85(4):644-5. doi: 10.4269/ajtmh.2011.10-0511.
Post kala-azar dermal leishmaniasis (PKDL) and mucosal leishmaniasis (ML) are serious clinical forms of leishmaniasis caused by Leishmania donovani parasites in Sudan. Although pentavalent antimonys are used as the first line of treatment of all clinical forms of leishmaniasis, persistent PKDL and ML patients are treated with liposomal amphotericin B (Ambisome) as a second-line drug. In this work, we report the development of allergic reactions by a PKDL and a ML Sudanese patient to Ambisome. The findings warrant future close supervision of patients to be treated with the drug.
Post kala-azar dermal leishmaniasis (PKDL) 和黏膜性利什曼病 (ML) 是由苏丹的利什曼原虫寄生虫引起的利什曼病的严重临床形式。尽管五价锑被用作所有临床形式利什曼病的一线治疗药物，但持续性 PKDL 和 ML 患者仍使用脂质体两性霉素 B（Ambisome）作为二线药物进行治疗。在这项工作中，我们报告了一名 PKDL 和一名 ML 苏丹患者对 Ambisome 产生过敏反应的情况。这些发现需要对接受该药物治疗的患者进行密切监督。
